secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2026-04-14T23:59:59+00:00
Accession:  0001438533-26-000032
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Travere's FILSPARI for FSGS without nephrotic syndrome, expanding label beyond IgAN
--------------------------------------------------------------------------------

- FDA approved FILSPARI (sparsentan) for FSGS without nephrotic syndrome in patients aged 8+, second indication.
- Addressable U.S. population estimated >30,000 individuals with FSGS without nephrotic syndrome.
- Phase 3 DUPLEX: 48% proteinuria reduction in non-nephrotic patients vs 27% irbesartan (p=0.0075).
- eGFR benefit: treatment difference 1.1 mL/min/1.73m2 at Week 108 favoring FILSPARI.
- Safety profile comparable to irbesartan, consistent with prior programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000032/0001438533-26-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000032/tvtx-20260413.htm
  HTML page:      https://secwatch.observer/filing/0001438533-26-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer